STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.

Publication

STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.

Journal Paper/Review - Oct 31, 2024

Woelfel Simon, Junker Daniel, Bergamin Irina, Meyer-Herbon Pamela, Stillhard Roman, Graf Nicole, Leinenkugel Georg, Dütschler Joel, König Marius, Kammerlander Livia, Häuptle Rahel, Zwyssig Sarah, Krieger-Grübel Claudia, Truniger Samuel, Koller Seraina, Metzger-Peter Katline, Frei Nicola Fabian, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich Werner, Friedrich Matthias, Bernsmeier Christine, Niess Jan-Hendrik, Korte Wolfgang C, Bürgi Justus J, Dulovic Alex, Schneiderhan-Marra Nicole, Semela David, Brand Stephan

Citation

Woelfel S, Junker D, Bergamin I, Meyer-Herbon P, Stillhard R, Graf N, Leinenkugel G, Dütschler J, König M, Kammerlander L, Häuptle R, Zwyssig S, Krieger-Grübel C, Truniger S, Koller S, Metzger-Peter K, Frei N, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Bernsmeier C, Niess J, Korte W, Bürgi J, Dulovic A, Schneiderhan-Marra N, Semela D, Brand S. STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease. Vaccines (Basel) 2024; 12

Type

Journal Paper/Review (English)

Journal

Vaccines (Basel) 2024; 12

Publication Date

Oct 31, 2024

Issn Print

2076-393X

Brief description/objective

Patients with chronic liver disease (CLD) have impaired vaccine immunogenicity and an excess risk of severe COVID-19. While variant-adapted COVID-19 mRNA vaccines are recommended for vulnerable individuals, their efficacy in patients with CLD has not been studied.